At the time of writing, Affimed N.V. [AFMD] stock is trading at $5.30, down -0.56%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AFMD shares have gain 5.16% over the last week, with a monthly amount drifted -10.17%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, March 2024, Affimed Reports 2023 Financial Results and Operational Progress. In a post published today on Yahoo Finance, AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024.
From an analyst’s perspective:
Affimed N.V. [NASDAQ: AFMD] stock has seen the most recent analyst activity on December 12, 2022, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $6. Previously, Stifel downgraded its rating to Hold on October 10, 2022, and dropped its price target to $2. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $7 on March 31, 2022. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $12 as its price target on February 23, 2022. Truist started tracking with a Buy rating for this stock on October 21, 2021, and assigned it a price target of $10. In a note dated September 30, 2021, Stifel initiated an Buy rating and provided a target price of $12 on this stock.
For the past year, the stock price of Affimed N.V. fluctuated between $2.23 and $11.10. Affimed N.V. [NASDAQ: AFMD] shares were valued at $5.30 at the most recent close of the market.
Analyzing the AFMD fundamentals
According to Affimed N.V. [NASDAQ:AFMD], the company’s sales were 19.87M for trailing twelve months, which represents an -85.76% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -6.1%, Pretax Profit Margin comes in at -6.27%, and Net Profit Margin reading is -6.44%. To continue investigating profitability, this company’s Return on Assets is posted at -1.02, Equity is -1.08 and Total Capital is -1.27. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.13 points at the first support level, and at 4.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.45, and for the 2nd resistance point, it is at 5.60.
Affimed N.V. [AFMD] reported earnings per share of -$1.73 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$2/share, meaning a difference of $0.27 and a surprise factor of 13.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$2.17 per share as compared to estimates of -$2.05 per share, a difference of -$0.12 representing a surprise of -5.90%.
Ratios To Look Out For
It is important to note that Affimed N.V. [NASDAQ:AFMD] has a current ratio of 3.70. Also, the Quick Ratio is 3.67, while the Cash Ratio stands at 2.17. Considering the valuation of this stock, the price to sales ratio is 3.98, the price to book ratio is 9.78.
